Precision Biosciences (DTIL) Liabilities and Shareholders Equity (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $143.9 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $143.9 million, up 15.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $500.7 million (down 13.64% YoY), and the FY2025 annual result was $154.4 million, up 13.22% from the prior year.
• Liabilities and Shareholders Equity retreated to $143.9 million in Q1 2026 per DTIL's latest filing, from $154.4 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $297.2 million in Q2 2022 and troughed at $93.5 million in Q3 2025.
• A 5-year average of $174.4 million and a median of $164.3 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity increased 29.14% in 2022, then sank 39.52% in 2023.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $238.2 million in 2022, then plunged by 32.91% to $159.8 million in 2023, then retreated by 14.64% to $136.4 million in 2024, then grew by 13.22% to $154.4 million in 2025, then retreated by 6.82% to $143.9 million in 2026.
• Business Quant data shows DTIL's Liabilities and Shareholders Equity at $143.9 million in Q1 2026, $154.4 million in Q4 2025, and $93.5 million in Q3 2025.